Catalyst Short Term Debt from 2010 to 2024

CPRX Stock  USD 22.11  0.37  1.70%   
Catalyst Pharmaceuticals Short Term Debt yearly trend continues to be fairly stable with very little volatility. Short Term Debt will likely drop to about 295.6 K in 2024. During the period from 2010 to 2024, Catalyst Pharmaceuticals Short Term Debt regression line of annual values had r-squared of  0 and arithmetic mean of  289,584. View All Fundamentals
 
Short Term Debt  
First Reported
2011-09-30
Previous Quarter
385 K
Current Value
393 K
Quarterly Volatility
92.8 K
 
Yuan Drop
 
Covid
Check Catalyst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Catalyst Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 5 M, Other Operating Expenses of 327 M or Operating Income of 91.2 M, as well as many indicators such as Price To Sales Ratio of 4.26, Dividend Yield of 0.0 or PTB Ratio of 4.38. Catalyst financial statements analysis is a perfect complement when working with Catalyst Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Catalyst Pharmaceuticals Correlation against competitors.
For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.

Latest Catalyst Pharmaceuticals' Short Term Debt Growth Pattern

Below is the plot of the Short Term Debt of Catalyst Pharmaceuticals over the last few years. It is Catalyst Pharmaceuticals' Short Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Catalyst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Short Term Debt10 Years Trend
Very volatile
   Short Term Debt   
       Timeline  

Catalyst Short Term Debt Regression Statistics

Arithmetic Mean289,584
Geometric Mean262,824
Coefficient Of Variation25.78
Mean Deviation34,744
Median300,518
Standard Deviation74,656
Sample Variance5.6B
Range340K
R-Value(0.05)
Mean Square Error6B
R-Squared0
Significance0.86
Slope(806.90)
Total Sum of Squares78B

Catalyst Short Term Debt History

2024295.6 K
2023369 K
2022337 K
2021308 K
202029 K

About Catalyst Pharmaceuticals Financial Statements

Catalyst Pharmaceuticals investors use historical fundamental indicators, such as Catalyst Pharmaceuticals' Short Term Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Catalyst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Short Term Debt369 K295.6 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Catalyst Stock Analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.